Io Therapeutics is a pharma company, focused on developing small molecule therapeutics for the treatment of CNS, cancer and autoimmune diseases.
IO Therapeutics Inc
In Feb 2013, Io Therapeutics entered into collaboration with the Michael J. Fox Foundation for Parkinsons Research (MJFF) for the evaluation of IRX4204 as a potential treatment for Parkinsons disease.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/io-therapeutics” connections=”true” suffix=””]
In Aug 2015, Io Therapeutics received funding from National Multiple Sclerosis Society through Fast Forward to support further evaluation of IRX4204 as potential treatment to stimulate repair of myelin, which is damaged in Multiple Sclerosis.